Dynavax Technologies Corporation

NasdaqGS:DVAX Lagerbericht

Marktkapitalisierung: US$1.5b

Dynavax Technologies Management

Management Kriterienprüfungen 4/4

Dynavax Technologies' CEO ist Ryan Spencer, ernannt in Dec 2019, hat eine Amtszeit von 4.42 Jahren. Die jährliche Gesamtvergütung beträgt $5.81M, bestehend aus 13.1% Gehalt und 86.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.18% der Aktien des Unternehmens, im Wert von $2.62M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.3 Jahre bzw. 5.9 Jahre.

Wichtige Informationen

Ryan Spencer

Geschäftsführender

US$5.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts13.1%
Amtszeit als Geschäftsführer4.5yrs
Eigentum des Geschäftsführers0.2%
Durchschnittliche Amtszeit des Managements3.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder6yrs

Jüngste Management Updates

Recent updates

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

May 22
Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

May 10

Dynavax: Holding Firm Despite Its Missing Cash Cow

Mar 23

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Mar 06
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Jan 31
Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Aug 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

Jun 02
Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

May 03
We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Jan 16
Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Clover, Dynavax COVID-19 vaccine gets EU GMP certificate

Sep 20

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Sep 12
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

The Alphavaxers: Dynavax And Novavax, 2 Quarters On

Aug 22

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats

Aug 04

Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Jun 03
Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Dynavax: Evolving Endemic Situation Adds To Its Risk

May 23

Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

May 12
Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

May 10
Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

Dynavax Technologies: Full Speed Ahead

Mar 01

Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Jan 28
Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Dynavax: A Coronavirus Growth Story

Jan 17

Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 18
Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

The Momentum Investor: Spotlight On Dynavax Technologies

Oct 25

Dynavax And TLR Biology: Long-Delayed But Outstanding Success

Oct 16

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

Oct 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts

Aug 10
Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts

Dynavax: Earnings This Year Ought To Surprise To The Upside

Aug 01

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Ryan Spencer im Vergleich zu den Einnahmen von Dynavax Technologies verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2024n/an/a

US$9m

Dec 31 2023US$6mUS$760k

-US$6m

Sep 30 2023n/an/a

US$61m

Jun 30 2023n/an/a

US$111m

Mar 31 2023n/an/a

US$236m

Dec 31 2022US$6mUS$695k

US$293m

Sep 30 2022n/an/a

US$320m

Jun 30 2022n/an/a

US$228m

Mar 31 2022n/an/a

US$104m

Dec 31 2021US$5mUS$600k

US$72m

Sep 30 2021n/an/a

-US$39m

Jun 30 2021n/an/a

-US$6m

Mar 31 2021n/an/a

-US$62m

Dec 31 2020US$2mUS$515k

-US$75m

Sep 30 2020n/an/a

-US$97m

Jun 30 2020n/an/a

-US$138m

Mar 31 2020n/an/a

-US$129m

Dec 31 2019US$3mUS$391k

-US$156m

Vergütung im Vergleich zum Markt: RyanDie Gesamtvergütung ($USD5.81M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD5.67M).

Entschädigung vs. Einkommen: RyanDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Ryan Spencer (46 yo)

4.5yrs

Amtszeit

US$5,810,736

Vergütung

Mr. Ryan Spencer serves as Independent Director at Cidara Therapeutics, Inc. from April 24, 2024. He serves as Interim Chief Financial Officer of Dynavax Technologies Corporation since March 29, 2024. He s...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Ryan Spencer
CEO, Interim CFO & Director4.5yrsUS$5.81m0.18%
$ 2.7m
David Novack
President & COO11.3yrsUS$2.99m0.024%
$ 368.7k
Robert Janssen
Chief Medical Officer and Senior VP of Clinical Development10.9yrsUS$1.88m0.049%
$ 742.1k
Kelly MacDonald
Senior VP & CFO (Leave of Absence)less than a yearUS$2.07m0.0059%
$ 88.9k
Justin Burgess
Chief Accounting Officer & Controller4.1yrskeine Datenkeine Daten
Jeff Coon
Senior VP & Chief Human Resources Officer5.4yrskeine Datenkeine Daten
Paul Cox
VP of Investor Relations & Corporate Communications1.4yrskeine Datenkeine Daten
John Slebir
Senior VP & General Counsel3yrskeine Datenkeine Daten
Donn Casale
Senior VP & Chief Commercial Officerno datakeine Datenkeine Daten
Dong Yu
Senior Vice President of Vaccine Research3.3yrskeine Datenkeine Daten
Eric Frings
VP, Site Head & MD for Dynavax GmbH3.4yrskeine Datenkeine Daten
Todd Lopeman
Senior Vice President of Technical Operations3.4yrskeine Datenkeine Daten

3.4yrs

Durchschnittliche Betriebszugehörigkeit

59.5yo

Durchschnittliches Alter

Erfahrenes Management: DVAXDas Führungsteam des Unternehmens gilt als erfahren (3.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Ryan Spencer
CEO, Interim CFO & Director4.5yrsUS$5.81m0.18%
$ 2.7m
Peggy Phillips
Independent Director17.8yrsUS$298.73k0.021%
$ 320.4k
Daniel Kisner
Independent Director13.9yrsUS$290.73k0.0011%
$ 17.4k
Francis Cano
Independent Director14.6yrsUS$278.73k0.016%
$ 240.7k
Robert Coffman
Member of Scientific Advisory Board1.4yrsUS$1.83mkeine Daten
Drew Pardoll
Member of Scientific Advisory Board6yrskeine Datenkeine Daten
Julie Eastland
Independent Director3.9yrsUS$293.73k0%
$ 0
Stanley Plotkin
Member of Scientific Advisory Board6yrsUS$20.00kkeine Daten
Scott Myers
Independent Chairman of the Board2.7yrsUS$323.73k0%
$ 0
Miriam Merad
Member of Scientific Advisory Board6yrskeine Datenkeine Daten
Laura Q. Chow
Member of Scientific Advisory Board6yrskeine Datenkeine Daten
E. Wherry
Member of Scientific Advisory Board6yrskeine Datenkeine Daten

6.0yrs

Durchschnittliche Betriebszugehörigkeit

73.5yo

Durchschnittliches Alter

Erfahrener Vorstand: DVAXDie Vorstandsmitglieder gelten als erfahren (5.9 Jahre durchschnittliche Amtszeit).